Innate Pharma

Regulatory Filings • Jul 2, 2012

ALL PROPOSED RESOLUTIONS AT THE ANNUAL GENERAL MEETING OF JUNE 28, 2012 WERE VOTED ACCORDING TO MANAGEMENT'S RECOMMENDATIONS

Marseilles, France, July 2, 2012

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual General Meeting ("AGM") took place on June 28, 2012, in Marseilles, France.

A number of 21,148,778 votes were expressed out of a total of 37,558,711 shares with voting rights, representing a quorum of 56.3%. All resolutions were voted in accordance with the management's recommendations. Details of the votes are available on Innate Pharma's website, investors section.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approach has been validated by licence agreements with two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 80 employees as at March 31, 2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press

Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mob.: +33 (0)6 26 94 18 53 investors@innate-pharma.com mb@atcg-partners.com

Marielle Bricman